Communiqués Cosmos Health Inc.

Actions

COSM

US2214133058

Produits pharmaceutiques

Temps réel estimé Cboe BZX 16:22:52 18/09/2026			Varia. 5j.	Varia. 1 janv.
0,3380 ^USD	+14,07%		+33,24%	-32,15%

11/09	Une filiale de Cosmos Health conclut un contrat de fabrication de 5 ans avec Viofar pour un traitement cardiovasculaire	MT
03/09	Cosmos Health Inc. réaffirme ses prévisions de résultats pour les exercices 2026, 2027 et 2029	CI

Communiqués

15/09	Cosmos Health Adds 5.2 Million Units in New Five-Year Agreements with Target Pharma; Orderbook Surges Past 32.7 Million Units, Up 31% Since June	AQ
14/09	Cosmos Health Moves to Tokenize CCX0722 Intellectual Property in Innovative Non-Dilutive Structure, Eyes $562 Billion Weight-Management Market	AQ
11/09	Cosmos Health Secures Additional 2.5 Million Units Under New Five-Year Contract Manufacturing Agreement with Viofar; Total Orderbook Surpasses 27.5 Million Units	AQ
09/09	Cosmos Health Launches C-ScrubVet in the UK, Advancing into the $69 Billion Global Animal Health Market	AQ
03/09	Cosmos Health: A Company Transformed — 2026 Year-to-Date	GL
31/08	Cosmos Health Strengthens Balance Sheet and Streamlines Capital Structure, Retires $8M ATW Convertible Note One Year Ahead of Maturity, Eliminating Further Dilution from Conversions	AQ
28/08	Cosmos Health Strengthens Balance Sheet and Streamlines Capital Structure; Retires $8M ATW Convertible Note One Year Ahead of Maturity, Eliminating Further Dilution From Conversions	GL
24/08	Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories	GL
20/08	Cosmos Health Enters Saudi Arabia Through Exclusive Distribution Agreement With Innova Healthcare; Secures Initial Purchase Order of 126,000 Sky Premium Life Units, With More Than 5 Million Units Expected Over Initial 5-Year Term	GL
19/08	Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurchase Program Underway	GL
19/08	Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurchase Program Underway	AQ
27/07	Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels	GL
20/07	Cosmos Health Expands Pharma Cell Partnership in Albania with Annualized Orders Projected to Exceed 54,000 Units	GL
17/07	Cosmos Health Share Buyback Expands to 5.11 Million Shares; Continues Open Market Repurchases	GL
16/07	Cosmos Health Share Buyback Surpasses $1 Million, Reaching 4.84 Million Shares; Continues Open Market Repurchases	GL
15/07	Cosmos Health Share Buyback Surpasses 4.5 Million Shares; Continues Open Market Repurchases	GL
14/07	Cosmos Health Share Buyback Expands to 4.49 Million Shares; Continues Open Market Repurchases	GL
13/07	Cosmos Health Share Buyback Reaches 4.36 Million Shares; Continues Open Market Repurchases	GL
13/07	Cosmos Health Accelerates Prescription Medicine Strategy with Libytec Partnership to Commercialize DIABIT-IS X in Greece	GL
10/07	Cosmos Health Launches Subscription Model	GL
09/07	Cosmos Health Expands Share Buyback to 4.14 Million Shares; Continues Open Market Repurchases	GL
08/07	Cosmos Health Share Buyback Surpasses 4 Million Shares; Continues Open Market Repurchases	GL
07/07	Cosmos Health Share Buyback Expands to 3.87 Million Shares; Continues Open Market Repurchases	GL
07/07	Cosmos Health Reports Preliminary Record Q2 and H1 2026 Revenue, Up Over 30% Year-Over-Year; Continues Open Market Share Repurchases	GL
06/07	Cosmos Health Share Buyback Increases to 3.64 Million Shares; Continues Open Market Purchases	GL